Zwong
2021-11-09
Pzifer better
U.S. government to buy $1 billion more worth of Merck's COVID-19 pill<blockquote>美国政府将再购买价值10亿美元的默克COVID-19药物</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
1
1
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":844740151,"tweetId":"844740151","gmtCreate":1636464067911,"gmtModify":1636464072750,"author":{"id":3583468248308610,"idStr":"3583468248308610","authorId":3583468248308610,"authorIdStr":"3583468248308610","name":"Zwong","avatar":"https://static.tigerbbs.com/3635e640fc53c5d93e114ddf330b36d7","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":3,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Pzifer better</p></body></html>","htmlText":"<html><head></head><body><p>Pzifer better</p></body></html>","text":"Pzifer better","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/844740151","repostId":1133150195,"repostType":4,"repost":{"id":"1133150195","kind":"news","pubTimestamp":1636463600,"share":"https://www.laohu8.com/m/news/1133150195?lang=zh_CN&edition=full","pubTime":"2021-11-09 21:13","market":"us","language":"en","title":"U.S. government to buy $1 billion more worth of Merck's COVID-19 pill<blockquote>美国政府将再购买价值10亿美元的默克COVID-19药物</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1133150195","media":"Reuters","summary":"Nov 9 (Reuters) - The U.S. government will buy another $1 billion worth of the COVID-19 pill made by","content":"<p>Nov 9 (Reuters) - The U.S. government will buy another $1 billion worth of the COVID-19 pill made by Merck & Co Inc(MRK.N)and partner Ridgeback Biotherapeutics, the companies said on Tuesday.</p><p><blockquote>路透11月9日-美国政府将再购买价值10亿美元的默克公司(MRK.N)及其合作伙伴Ridgeback Biotherapeutics周二表示。</blockquote></p><p> The government in June agreed to buy 1.7 million courses of molnupiravir for $1.2 billion and is now exercising options to buy 1.4 million more.</p><p><blockquote>政府在6月份同意以12亿美元购买170万个疗程的莫努匹拉韦，现在正在行使选择权再购买140万个疗程。</blockquote></p><p> That brings the total secured courses to 3.1 million and worth $2.2 billion. Merck said the government has the right to buy 2 million more courses as part of the contract.</p><p><blockquote>这使得安全课程总数达到310万门，价值22亿美元。默克表示，作为合同的一部分，政府有权再购买200万门课程。</blockquote></p><p> The drug has been closely watched since data last month showed that when given early in the illness it could halve the chances of dying or being hospitalized for those most at risk of developing severe COVID-19.</p><p><blockquote>自上个月的数据显示，如果在疾病早期服用，该药物可以将最有可能患严重COVID-19的人的死亡或住院几率减半以来，该药物一直受到密切关注。</blockquote></p><p> \"Molnupiravir, if authorized, will be among the vaccines and medicines available to fight COVID-19 as part of our collective efforts to bring this pandemic to an end,\" said Frank Clyburn, president of Merck's human health business.</p><p><blockquote>默克人类健康业务总裁弗兰克·克莱伯恩(Frank Clyburn)表示：“如果获得授权，莫努匹拉韦将成为可用于对抗COVID-19的疫苗和药物之一，作为我们结束这一流行病的集体努力的一部分。”</blockquote></p><p> With limited options to treat people with COVID-19, the U.S government has also secured millions of doses of Pfizer Inc's(PFE.N)rival antiviral drug, which last week was shown to cut by 89% the chance of hospitalization or death for adults at risk of severe disease.</p><p><blockquote>由于治疗COVID-19患者的选择有限，美国政府还获得了数百万剂辉瑞公司(PFE)的抗病毒药物。上周显示，该药物可将有严重疾病风险的成年人住院或死亡几率降低89%。</blockquote></p><p> Merck's application with the U.S. Food and Drug Administration will be taken up by a panel of independent experts on Nov. 30, following which the regulator is expected to make a decision.</p><p><blockquote>默克公司向美国提出的申请。美国食品和药物管理局将于11月30日由一个独立专家小组接管，随后监管机构预计将做出决定。</blockquote></p><p> Britain last week became the first country in the world to clear the use of molnupiravir.</p><p><blockquote>英国上周成为世界上第一个批准使用莫努匹拉韦的国家。</blockquote></p><p> Merck expects to produce 10 million courses of the treatment by the end of this year, with at least 20 million set to be manufactured in 2022.</p><p><blockquote>默克预计到今年年底将生产1000万个疗程的治疗，其中至少2000万个疗程将在2022年生产。</blockquote></p><p> The drugmaker's shares rose nearly 1% to $83.41 in premarket trading.</p><p><blockquote>该制药商股价在盘前交易中上涨近1%至83.41美元。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. government to buy $1 billion more worth of Merck's COVID-19 pill<blockquote>美国政府将再购买价值10亿美元的默克COVID-19药物</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. government to buy $1 billion more worth of Merck's COVID-19 pill<blockquote>美国政府将再购买价值10亿美元的默克COVID-19药物</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Reuters</strong><span class=\"h-time small\">2021-11-09 21:13</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Nov 9 (Reuters) - The U.S. government will buy another $1 billion worth of the COVID-19 pill made by Merck & Co Inc(MRK.N)and partner Ridgeback Biotherapeutics, the companies said on Tuesday.</p><p><blockquote>路透11月9日-美国政府将再购买价值10亿美元的默克公司(MRK.N)及其合作伙伴Ridgeback Biotherapeutics周二表示。</blockquote></p><p> The government in June agreed to buy 1.7 million courses of molnupiravir for $1.2 billion and is now exercising options to buy 1.4 million more.</p><p><blockquote>政府在6月份同意以12亿美元购买170万个疗程的莫努匹拉韦，现在正在行使选择权再购买140万个疗程。</blockquote></p><p> That brings the total secured courses to 3.1 million and worth $2.2 billion. Merck said the government has the right to buy 2 million more courses as part of the contract.</p><p><blockquote>这使得安全课程总数达到310万门，价值22亿美元。默克表示，作为合同的一部分，政府有权再购买200万门课程。</blockquote></p><p> The drug has been closely watched since data last month showed that when given early in the illness it could halve the chances of dying or being hospitalized for those most at risk of developing severe COVID-19.</p><p><blockquote>自上个月的数据显示，如果在疾病早期服用，该药物可以将最有可能患严重COVID-19的人的死亡或住院几率减半以来，该药物一直受到密切关注。</blockquote></p><p> \"Molnupiravir, if authorized, will be among the vaccines and medicines available to fight COVID-19 as part of our collective efforts to bring this pandemic to an end,\" said Frank Clyburn, president of Merck's human health business.</p><p><blockquote>默克人类健康业务总裁弗兰克·克莱伯恩(Frank Clyburn)表示：“如果获得授权，莫努匹拉韦将成为可用于对抗COVID-19的疫苗和药物之一，作为我们结束这一流行病的集体努力的一部分。”</blockquote></p><p> With limited options to treat people with COVID-19, the U.S government has also secured millions of doses of Pfizer Inc's(PFE.N)rival antiviral drug, which last week was shown to cut by 89% the chance of hospitalization or death for adults at risk of severe disease.</p><p><blockquote>由于治疗COVID-19患者的选择有限，美国政府还获得了数百万剂辉瑞公司(PFE)的抗病毒药物。上周显示，该药物可将有严重疾病风险的成年人住院或死亡几率降低89%。</blockquote></p><p> Merck's application with the U.S. Food and Drug Administration will be taken up by a panel of independent experts on Nov. 30, following which the regulator is expected to make a decision.</p><p><blockquote>默克公司向美国提出的申请。美国食品和药物管理局将于11月30日由一个独立专家小组接管，随后监管机构预计将做出决定。</blockquote></p><p> Britain last week became the first country in the world to clear the use of molnupiravir.</p><p><blockquote>英国上周成为世界上第一个批准使用莫努匹拉韦的国家。</blockquote></p><p> Merck expects to produce 10 million courses of the treatment by the end of this year, with at least 20 million set to be manufactured in 2022.</p><p><blockquote>默克预计到今年年底将生产1000万个疗程的治疗，其中至少2000万个疗程将在2022年生产。</blockquote></p><p> The drugmaker's shares rose nearly 1% to $83.41 in premarket trading.</p><p><blockquote>该制药商股价在盘前交易中上涨近1%至83.41美元。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.reuters.com/world/us/us-government-buy-14-mln-more-courses-mercks-covid-19-pill-2021-11-09/\">Reuters</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东"},"source_url":"https://www.reuters.com/world/us/us-government-buy-14-mln-more-courses-mercks-covid-19-pill-2021-11-09/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133150195","content_text":"Nov 9 (Reuters) - The U.S. government will buy another $1 billion worth of the COVID-19 pill made by Merck & Co Inc(MRK.N)and partner Ridgeback Biotherapeutics, the companies said on Tuesday.\nThe government in June agreed to buy 1.7 million courses of molnupiravir for $1.2 billion and is now exercising options to buy 1.4 million more.\nThat brings the total secured courses to 3.1 million and worth $2.2 billion. Merck said the government has the right to buy 2 million more courses as part of the contract.\nThe drug has been closely watched since data last month showed that when given early in the illness it could halve the chances of dying or being hospitalized for those most at risk of developing severe COVID-19.\n\"Molnupiravir, if authorized, will be among the vaccines and medicines available to fight COVID-19 as part of our collective efforts to bring this pandemic to an end,\" said Frank Clyburn, president of Merck's human health business.\nWith limited options to treat people with COVID-19, the U.S government has also secured millions of doses of Pfizer Inc's(PFE.N)rival antiviral drug, which last week was shown to cut by 89% the chance of hospitalization or death for adults at risk of severe disease.\nMerck's application with the U.S. Food and Drug Administration will be taken up by a panel of independent experts on Nov. 30, following which the regulator is expected to make a decision.\nBritain last week became the first country in the world to clear the use of molnupiravir.\nMerck expects to produce 10 million courses of the treatment by the end of this year, with at least 20 million set to be manufactured in 2022.\nThe drugmaker's shares rose nearly 1% to $83.41 in premarket trading.","news_type":1,"symbols_score_info":{"MRK":0.9}},"isVote":1,"tweetType":1,"viewCount":919,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":12,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/844740151"}
精彩评论